Researchers have discovered a pair of drugs that work together to kill cancer cells and counter genetic mutations that cause diffuse midline gliomas.
The epigenetic histone mutation H3.1K27M works in combination with ACVR1 mutations to cause diffuse intrinsic pontine glioma tumors to form and grow quickly.
DIPG cancer cells exposed to MI-2 fail to maintain healthy levels of cholesterol and die quickly, by inhibiting lanosterol synthase. Additionally, while MI-2 destroys glioma cancer cells, the drug does not damage healthy brain cells.
A small molecule, 6-thio-dG, may provide a new approach to treating currently untreatable pediatric brain cancers, researchers report.
A fatal brain stem tumor was cleared by injecting it with engineered T-cells that recognized cancer and targeted it for destruction in mouse models, researchers report.
Based on a large scale meta analysis, researchers report striking differences between children's high grade gliomas, so much so that they could be split into 10 different subtypes based on different characteristics. The findings have important implications for developing new and individualized treatments.
Targeting a protein called neuroligin 3 helps stop the growth of high grade gliomas in mice, a new study reports.
Researchers use PET neuroimaging technology to help determine which children with DIPG brain cancer will benefit best from Avastin.
Researchers report an experimental treatment has shown to be able to stop treatment resistant glioblastoma in human cells and mouse models.
A new study reports panobinostat and other gene regulating drugs may prove helpful in the treatment of DIPG.
